Varenicline, smoking cessation, and neuropsychiatric adverse events.
about
Nicotine receptor partial agonists for smoking cessationFlexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trialAre Smoking Cessation Treatments Associated with Suicidality Risk? An OverviewVarenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherenceUpdate on medicines for smoking cessationSmoking Use and Cessation Among People with Serious Mental IllnessNon-psychotropic medication and risk of suicide or attempted suicide: a systematic reviewRisk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysisVarenicline as a Cause of Suicidal OutcomesVarenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized TrialVarenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort studyRationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinicsMaintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.Tobacco use treatment in primary care patients with psychiatric illness.Varenicline in the treatment of alcohol use disorders.Tobacco use and cessation for cancer survivors: an overview for cliniciansUse of pharmacotherapies for smoking cessation: analysis of pregnant and postpartum Medicaid enrolleesTreatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practicesUse of stop-smoking medications in the United States before and after the introduction of vareniclineWhy Don't Smokers Want Help to Quit? A Qualitative Study of Smokers' Attitudes towards Assisted vs. Unassisted Quitting.Trends in Use of Medications for Smoking Cessation in Medicare, 2007-2012Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessationQuitting smoking before and after varenicline: a population study based on two representative samples of US smokersCancer screening, prevention, and treatment in people with mental illness.Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis.Role of nicotine receptor partial agonists in tobacco cessation.Smoking and mental illness. An update for psychiatrists.Use of Varenicline in Smokeless Tobacco Cessation: A Systematic Review and Meta-Analysis.The safety of treatments for tobacco use disorder.How do smoking cessation medicines compare with respect to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness analysis.Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States.Treatment with bupropion and varenicline for smoking cessation and the risk of acute cardiovascular events and injuries: a Swedish case-crossover study.Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis.Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations.Effects of Televised Direct-to-Consumer Advertising for Varenicline on Prescription Dispensing in the United States, 2006-2009.Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis.Evaluation of Prolonged Exposure to Varenicline in Adult Rats: Hematological, Biochemical and Anatomopathological Studies.Differential effects of α4β2 nicotinic receptor antagonists and partial-agonists on contextual fear extinction in male C57BL/6 mice.Improvement of Smoking Abstinence Rates With Increased Varenicline Dosage: A Propensity Score-Matched Analysis.
P2860
Q24185773-00317A22-0531-4506-A6E0-0C5368AF1A74Q24658591-CAAC8EB5-4A4A-42F7-8E7A-5C8E6756DE86Q26747804-0F90CE40-278F-4934-96AF-9464B726BF65Q26751374-DB819ED9-5C50-431A-9175-E443501A0975Q26773281-C78361C9-CC58-489D-B210-F28F4F7C4B3CQ26785461-C402BF6F-7E81-4F31-A380-ABFFA4CF1B8BQ28078315-B848B425-F7A8-43BB-9780-F6BEC9183E11Q28083649-199A3806-F57E-42DE-A819-0BDA33CBB497Q28255130-99990DD6-58B6-4DE0-808E-020610410B50Q28552053-8BA4AC88-746D-4197-A143-7682D6568158Q28646213-30FCE67D-D931-4BCD-8E83-7E3756EF0663Q33854297-FDFCE2B8-DB26-46CA-A6A4-1D0D7070C8ADQ34014716-25E3D6A0-7D98-4587-9F39-EF349813B46EQ34725293-80630799-1408-4FCF-8FD7-7583086CE56CQ35219810-B2EF18ED-0C64-4576-BF22-BA764AF9D86CQ35226577-D966232C-0267-43CB-AAC1-9A1ED802C104Q35516430-9277657C-282A-43CC-959E-090B301EFFB3Q35701489-501A9841-92E2-4619-B40F-4A30A45FCB67Q35747407-8693216D-2D5E-4B71-86F0-5DF2591DCD6EQ35791022-57A825F2-D810-404C-86C5-552FAD980F55Q35977030-B14479A0-88C4-4FBB-A799-D119CC091D2AQ36377890-910D16EE-B36C-4956-A4EE-AADF5C364814Q36486726-05B00A4D-6331-41E2-9E2D-319F1095E690Q36590602-9F305694-D34D-44B6-8197-8B7B602762BDQ36665194-FC866568-B5EB-40E6-ADC2-C4943B551A1CQ36711713-1808D2B5-D153-4ADD-B0FB-0C697ED482D4Q37589870-2734D9BE-88D8-4A02-93A7-6846D5ED9AE0Q38290164-EB978945-6076-418D-82C0-476DCC1BC2A1Q38342207-0F3DC742-9132-4FD0-8D0B-2F74F954A361Q38682466-4333980A-BD2C-4D35-9C27-8C0AE558C6C6Q38720906-58A63B58-A3E3-42B1-A5A8-DB58F4EADC49Q38729731-0A0C511C-896E-47CA-9A8D-519BD9314BDAQ38736026-32A5EDAA-4681-4509-83A4-7F4A48697FADQ38797685-28FE73D1-16D9-488C-AC89-3F2FF1CD94ABQ39333786-EFE590E2-CA33-4D51-9A6D-2954D071BCDEQ40523144-6D9781C2-FD2B-42AB-8357-2F8670724408Q40587312-073F13C4-9DC1-4C1B-841F-7F3AF7128E9DQ46301289-C66E6A8C-2B4E-4613-937F-99CDE8E29ADFQ48518738-08770B35-7A1F-4CD5-B4CC-7E4594C26917Q49897203-DE67364A-2228-4BEA-8A9E-698CE8A1C3FE
P2860
Varenicline, smoking cessation, and neuropsychiatric adverse events.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Varenicline, smoking cessation, and neuropsychiatric adverse events.
@ast
Varenicline, smoking cessation, and neuropsychiatric adverse events.
@en
Varenicline, smoking cessation, and neuropsychiatric adverse events.
@nl
type
label
Varenicline, smoking cessation, and neuropsychiatric adverse events.
@ast
Varenicline, smoking cessation, and neuropsychiatric adverse events.
@en
Varenicline, smoking cessation, and neuropsychiatric adverse events.
@nl
prefLabel
Varenicline, smoking cessation, and neuropsychiatric adverse events.
@ast
Varenicline, smoking cessation, and neuropsychiatric adverse events.
@en
Varenicline, smoking cessation, and neuropsychiatric adverse events.
@nl
P2860
P1476
Varenicline, smoking cessation, and neuropsychiatric adverse events.
@en
P2093
J John Mann
Robert D Gibbons
P2860
P304
P356
10.1176/APPI.AJP.2013.12121599
P407
P577
2013-12-01T00:00:00Z